Kenneth Kalunian

Has grant

Professor of Medicine

University of California, San Diego

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Kenneth Kalunian is a faculty member at the University of California, San Diego, specializing in Medicine. His research primarily focuses on the placebo effect in knee osteoarthritis, systemic lupus erythematosus (SLE) treatment efficacy, and the immunophenotyping of lupus nephritis. Recent publications include contributions to clinical guidelines and innovative studies on lupus nephritis outcomes and treatment responses.

Recent Grants

Grant: Close

Assessing Lupus: Developing a Novel Outcome Approach for Clinical Trials

Open Date: 2021-01-20

Close Date: 2023-01-19

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (5)

Brad H Rovin

The Ohio State University Wexner Medical Center

UNITED STATES

View details

Severin Ruoss

University of California, San Diego

UNITED STATES

View details

Fan Zhang

Assistant Professor

University of Colorado Boulder

UNITED STATES

View details

Jun Inamo

Assistant Professor (part-time)

Keio University

JAPAN

View details

Jessica Greco

Assistant Professor of Medicine

Ohio State University Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kenneth Kalunian

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Placebo Effect Sizes in Clinical Trials of Knee Osteoarthritis Using Intra‐Articular Injections of Biologic Agents

Reassessing antimalarial use in long-term SLE clinical trials – Authors' reply

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial

Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis

NONINVASIVE HIGH-THROUGHPUT SERUM PROTEOMICS FOR DISTINGUISHING SUBTYPES OF LUPUS NEPHRITIS

PROTEOMIC ANALYSIS OF SERUM OVER TIME TO FORECAST TREATMENT RESPONSE IN LUPUS NEPHRITIS

THE IMMUNE MAP OF LUPUS NEPHRITIS: A SPATIALLY-RESOLVED KIDNEY PROTEOMIC APPROACH

2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis

LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials

2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis

Collaborators (5)

Brad H Rovin

Severin Ruoss

Fan Zhang

Jun Inamo

Jessica Greco

Make your next move.